Global Low-Density Lipoprotein (LDL) Test Market, By Type (LDL-C, LDL-P, LDL-B, Others), Component (Kits and Reagents, Devices, Services), Disease (Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidaemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Others), Distribution Channel (Direct Tenders, Retail), End User (Hospitals, Clinics, Ambulatory Care, Research Laboratory, Others) – Industry Trends and Forecast to 2030.
Low-Density Lipoprotein (LDL) Test Market Analysis and Size
According to the Centers for Disease Control and Prevention, 71 million people in the United States have high levels of LDL, or bad cholesterol. Only two out of every three people with LDL cholesterol have it under control. The low-density lipoprotein (LDL) test market is expected to grow rapidly over the forecast period due to the rising prevalence of chronic diseases. As a result of these factors, the low-density lipoprotein (LDL) test was introduced into the healthcare industry.
Data Bridge Market Research analyses that the low-density lipoprotein (LDL) test market which is USD 8575.99 million in 2022, is expected to reach USD 13772.33 million by 2030, at a CAGR of 6.1% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Low-Density Lipoprotein (LDL) Test Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (LDL-C, LDL-P, LDL-B, Others), Component (Kits and Reagents, Devices, Services), Disease (Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidaemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Others), Distribution Channel (Direct Tenders, Retail), End User (Hospitals, Clinics, Ambulatory Care, Research Laboratory, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Abbott (U.S.), QIAGEN (Germany), Quest Diagnostics Incorporated (U.S.), Sekisui Diagnostics (U.S.), Express Biotech International (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Randox Laboratories Ltd. (England), Diasys Diagnostic Systems GmbH (Germany), Reckondiagnostics (India), Eurolyser Diagnostica GmbH (Austria), Diazyme Laboratories, Inc. (Germany), Laboratory Corporation of America Holdings. (U.S.), Cell Biolabs, Inc. (U.S.), Atlas Medical GmbH (U.K.), Eurofins Scientific (Luxembourg), Home Access Health (U.S.), Clinical Reference Laboratory, Inc. (U.S.), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
LDL blood tests are used to determine the amount of cholesterol in the blood. LDL testing can be used to determine LDL levels as part of a lipid panel or as a standalone test. Increased LDL cholesterol levels in an individual indicate a high risk of heart attack and stroke. The other four major types of lipoproteins are very low-density lipoprotein (VLDL), chylomicrons, intermediate-density lipoprotein (IDL), high-density lipoprotein (HDL) and low-density lipoprotein (LDL),. The primary function of lipoprotein particles is to transport lipids such as triglycerides and cholesterol in the blood between organs.
Low-Density Lipoprotein (LDL) Test Market Dynamics
Drivers
- Rising prevalence of chronic diseases
The low-density lipoprotein (LDL) test market is expected to grow rapidly during the forecast period because of the rising prevalence of chronic diseases. According to the Centers for Disease Control and Prevention, 71 million Americans have high LDL, or bad cholesterol levels. LDL cholesterol is under control in only two out of every three people. As a result of these factors, the low-density lipoprotein (LDL) test was introduced into the healthcare industry.
- Increasing the prevalence of heart diseases
The rising prevalence of chronic and cardiovascular diseases will inhibit the growth rate of the low-density lipoprotein (LDL) test market. High cholesterol levels have increased the prevalence of heart disorders such as hypertension, angina, stroke, carotid artery disease, and peripheral arterial disease. Hypertension is a worldwide problem caused by high cholesterol levels. Diabetes raises bad cholesterol and triglyceride levels while decreasing good cholesterol, increasing the risk of stroke and heart disease. These are the certain factors which drive the market growth.
Opportunities
- Rise in obesity and high cholesterol levels
According to the International Diabetes Federation, diabetes affected 8.8% of India's population in 2017. Obesity and high cholesterol levels are increasing in developing countries, contributing to an increase in the incidence of heart disease. Rising hypertension incidences in India have increased the prevalence of cardiac diseases, which is expected to support market growth.
Restraints/Challenges
- Lack of skilled professionals
The low-density lipoprotein (LDL) test market will be challenged by an unfavourable reimbursement scenario in developing and underdeveloped countries, as well as a shortage of skilled professionals. Furthermore, the emergence of unfavourable conditions as a result of the COVID-19 outbreak and growing concern about patient data security will act as a restraint and further impede the market's growth rate during the forecast period of 2023-2030.
This low-density lipoprotein (LDL) test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the low-density lipoprotein (LDL) test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2021, Verichem announced the release of its Ready-to-Use HDL/LDL Calibration Verification Kit. The kit is designed to meet the needs of a wide range of clinical laboratory workers, including those who perform routine diagnostic testing, medical research, and the development and support of in-vitro diagnostic (IVD) products.
Global Low-Density Lipoprotein (LDL) Test Market Scope
The low-density lipoprotein (LDL) test market is segmented on the basis of type, component, disease, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- LDL-C
- LDL-P
- LDL-B
- Others
Component
- Kits and Reagents
- Devices
- Services
Disease
- Diabetes
- Stroke
- Atherosclerosis
- Obesity
- Dyslipidaemia
- Carotid Artery Disease
- Peripheral Arterial Disease
- Angina
- Others
Distribution Channel
- Direct Tenders
- Retail
End User
- Hospitals
- Clinics
- Ambulatory Care
- Research Laboratory
- Others
Low-Density Lipoprotein (LDL) Test Market Regional Analysis/Insights
The low-density lipoprotein (LDL) test market is analysed and market size insights and trends are provided by country, type, component, disease, end user, and distribution channel as referenced above.
The countries covered in the low-density lipoprotein (LDL) test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the low-density lipoprotein (LDL) test market because of this region's increased prevalence of cardiovascular diseases. Furthermore, rising demand for preventive healthcare will boost the market's growth rate in this region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rising prevalence of chronic disease and improving healthcare infrastructure. Additionally, the rising geriatric population, rising geriatric population, and high demand for junk food will boost the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The low-density lipoprotein (LDL) test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for low-density lipoprotein (LDL) test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the low-density lipoprotein (LDL) test market. The data is available for historic period 2011-2021.
Competitive Landscape and Low-Density Lipoprotein (LDL) Test Market Share Analysis
The low-density lipoprotein (LDL) test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to low-density lipoprotein (LDL) test market.
Some of the major players operating in the low-density lipoprotein (LDL) test market are:
- Thermo Fisher Scientific Inc. (U.S.)
- BD (U.S.)
- Abbott (U.S.)
- QIAGEN (Germany)
- Quest Diagnostics Incorporated (U.S.)
- Sekisui Diagnostics (U.S.)
- Express Biotech International (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Randox Laboratories Ltd. (England)
- Diasys Diagnostic Systems GmbH (Germany)
- Reckondiagnostics (India)
- Eurolyser Diagnostica GmbH (Austria)
- Diazyme Laboratories, Inc. (Germany)
- Laboratory Corporation of America Holdings. (U.S.)
- Cell Biolabs, Inc. (U.S.)
- Atlas Medical GmbH (U.K.)
- Eurofins Scientific (Luxembourg)
- Home Access Health (U.S.)
- Clinical Reference Laboratory, Inc. (U.S.)
- Merck KGaA (Germany)
SKU-